DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Laquinimod is an investigational drug.
There have been 15 clinical trials for Laquinimod. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Teva Pharmaceutical Industries, Teva Branded Pharmaceutical Products, R&D Inc., and [disabled in preview].
Recent Clinical Trials for Laquinimod
|A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo||Teva Pharmaceutical Industries||Phase 2|
|A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod||Teva Branded Pharmaceutical Products, R&D Inc.||Phase 2|
|A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together||Teva Pharmaceutical Industries||Phase 1|